The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal

Table 1 Characteristics of the randomized controlled trials assessing the effect of prior preventive treatment failures on the treatment with erenumab for migraine prevention

	NCT02066415 [9,10,11,12,13]	STRIVE [14,15,16]	LIBERTY [17, 18]
Phase	II	III	IIIb
Migraine type	CM	EM	EM
Dose (mg)	70/140	70/140	140
OLE duration (weeks)	52	52	24
Duration of blind phase (weeks)	12	24	12
Prior preventive treatment failures^a accepted	≤3	≤2	2–4
No. of patients
Placebo	286	319	125
70 mg	191	317	–
140 mg	190	319	121
Patients with prior preventive treatment failure(s) (%)
Placebo	70	40	100
70 mg	67	40	–
140 mg	66	36	100

MMD Monthly Migraine Days, OLE Open-Label Extension, EM Episodic Migraine, CM Chronic Migraine
^adue to lack of response; partial response or suspension due to tolerability were accepted

ISSN: 1129-2377